Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears

Jan-Niklas Eckardt, Jan Moritz Middeke, Sebastian Riechert, Tim Schmittmann, Anas Shekh Sulaiman, Michael Kramer, Katja Sockel, Frank Kisschinsky, Ulrich Schuler, Johannes Schetelig, Christoph Röllig, Christian Thiede, Karsten Wendt and Martin Bornhäuser

© The Author(s) 2021

The evaluation of bone marrow morphology by experienced hematopathologists is essential in the diagnosis of acute myeloid leukemia (AML); however, it suffers from a lack of standardization and inter-observer variability. Deep learning (DL) can process medical image data and provides data-driven class predictions. Here, we apply a multi-step DL approach to automatically segment cells from bone marrow images, distinguish between AML samples and healthy controls with an area under the receiver operating characteristic (AUROC) of 0.9699, and predict the mutation status of Nucleophosmin 1 (NPM1)—one of the most common mutations in AML—with an AUROC of 0.92 using only image data from bone marrow smears. Utilizing occlusion sensitivity maps, we observed so far unreported morphologic cell features such as a pattern of condensed chromatin and perinuclear lightening zones in myeloblasts of NPM1-mutated AML and prominent nucleoli in wild-type NPM1 AML enabling the DL model to provide accurate class predictions.

Leukemia (2022) 36:111–118; https://doi.org/10.1038/s41375-021-01408-w

INTRODUCTION

A fundamental component in the diagnostic workflow of acute myeloid leukemia (AML) is cytomorphology [1]. The assessment of myeloblast counts and their morphology is essential for correct diagnosis, response assessment, and relapse detection. Cytomorphology may, in some cases, also lead to the suspicion of possible diagnosis, response assessment, and relapse detection. Cytomorphology and cell morphology is essential for correct diagnosis. The assessment of AML cytomorphology [1] is utilized for molecular risk stratification [5]. One of the most commonly mutated genes in AML is Nucleophosmin 1 (NPM1). It plays a critical role in disease initiation and is utilized for molecular risk stratification in the recent European Leukemia Net 2017 (ELN2017) recommendations [1]. Mutated NPM1 can be found in a third of all adult AML cases and up to 50–60% in AML with a normal karyotype [6, 7] and is considered a distinct disease entity in the current WHO classification [8]. So far, different morphological subtypes of AML according to the FAB classification [3] have been associated with different frequencies of NPM1 mutations [9]. However, the interpretation of cytomorphologic image data is subjective, time-consuming, and suffers from intra- and inter-observer variability [10, 11]. Artificial neural nets (ANN) have demonstrated excellent capabilities in the processing of large quantities of image data [12]. Deep learning (DL) models are large-scale ANN consisting of a multitude of interconnected parallel processing units called artificial neurons [13, 14]. Especially

convolutional neural nets (CNN) achieve outstanding results in image recognition [15]. These capabilities can be used for computer vision purposes in the diagnosis of acute leukemias [16–18].

In our study, we present a CNN-based scalable model that accurately distinguishes between AML cases and healthy subjects from digitalized bone marrow images. Further, our model accurately predicts NPM1 mutation status from bone marrow cytomorphology and unveils distinct morphologic features for the prediction of NPM1 mutation status.

METHODS

Data set and molecular analysis

We identified 1251 patients who have been newly diagnosed and treated with AML in the previously reported multicentric trials (AML96 [19], AML2003 [20], AMLCG1999 [21], AML60+ [22], AMLCG2008 [23], and SORAML [24]) or from the multicentric patient registry of the German Study Alliance Leukemia (SAL, NCT0188874) via retrospective chart review. Eligibility criteria for the AML cohort were newly diagnosed AML according to WHO criteria [8], age ≥18 years, and available biomaterial at initial diagnosis. A control cohort was comprised of 236 bone marrow samples from healthy bone marrow donors who underwent bone marrow donation at our center. Figure 1 shows the set-up of the study cohort and the split of augmented image data between training and test set (4:1). All mentioned studies were previously approved by the Institutional Review

Departments of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany. Institute of Circuits and Systems, Technical University Dresden, Dresden, Germany. German Consortium for Translational Cancer Research DKFZ, Heidelberg, Germany. National Center for Tumor Diseases (NCT), Dresden, Germany. These authors contributed equally: Jan-Niklas Eckardt, Jan Moritz Middeke. These authors contributed equally: Karsten Wendt, Martin Bornhäuser. Email: jan-niklas.eckardt@uniklinikum-dresden.de

Received: 30 April 2021 Revised: 12 August 2021 Accepted: 27 August 2021
Published online: 8 September 2021
Board of the Technical University Dresden. All participants gave their written informed consent according to the Declaration of Helsinki. The preparation of squash slides was performed from anticoagulated bone marrow by experienced laboratory technicians within 2 h after the sample was taken, as recommended by WHO guidelines [25]. Sample staining was performed with the May–Grunwald–Giemsa method [26]. Screening for NPM1 mutations was performed as described previously [27] and a 5% variant allele frequency (VAF) mutation cut-off was used. High-resolution pictures of representative regions of the bone marrow smears (BMS) were taken using the Nikon Eclipse E600 microscope (50-fold magnification) with the Nikon D5Fi2 mounted camera and Nikon Imaging Software Elements D4 for image processing. Corresponding regions of interest were manually selected by hematologists and measured 0.1775 × 0.1325 mm. For selection of archived BMS, image acquisition, and upload of images to the database, 10 min of manual labor were needed per case. Per case, a median of 168.5 cells were captured (interquartile range: 124–217). Samples were randomly assigned to either a training or a validation set with a split of 4:1.

**DL model**

A multi-step machine learning workflow with individual DL models for different tasks was set up as shown in Fig. 2: Step 1: BMS were digitized and uploaded to an online segmentation and labeling platform that we developed for the purpose of this work. A human-in-the-loop cell segmentation approach was performed by hematologists with a Faster Region-based Convolutional Neural Net [28] (FRCNN). First, initial segmentation was done with the VGG Image Annotator [29] tool. Then, the FRCNN was trained with the segmented images and created new segmentation proposals for unsegmented images which were manually corrected by hematologists. The loop was closed by the refinement of segmentation proposals and repeated network training. A quarter of cases was segmented using this human-in-the-loop approach while for the remainder of cases the FRCNN worked autonomously without the need for human intervention for re-segmentation of cells. This way, segmentation quality improved substantially over iterations eliminating the need for manual segmentation in the following unsegmented images. Additionally, hyperparameter optimization was performed automatically using the Optuna [30] framework with a predefined hyperparameter space. Step 2: Feature extraction was performed manually by hematologists. In all, 8500 individual cells were labeled according to lineage, cell type, and characteristics like Auer rods. Features like cell size, eccentricity, and color range were automatically derived by the computer vision algorithms. Step 3: For distinction between AML and healthy control samples based on segmented images, we trained a multitude of DL models for binary predictions of cell types and characteristics that expressed results as ratios (e.g. ratio of myeloblasts among all cells or features such as presence or absence of Auer rods). The aggregated results given by these individual models were used as input for an Ensemble Neural Net (ENN) for final classification decisions. Model architecture for the distinction between AML and healthy control samples was based on the Xception CNN [31] utilizing transfer learning. Xception architecture was modified to receive BMS images (2560 × 1920 pixels) as input at the top level. Fully connected output layers for the 2048-dimensional output vectors of the core Xception architecture were established via hyperparameter optimization. Hyperparameters differed between individual models. Step 4: For NPM1 status prediction, transfer learning with a ResNet50 [32] pretrained on ImageNet was utilized on BMS images. The ResNet50-architecture was modified to receive input sizes (2000 × 1500 pixels) and the output layer was reshaped to a fully connected layer with two neurons to accommodate the binary classification problem before retraining. Hyperparameter optimization was performed for learning rate, learning rate gamma, momentum, and weight decay. Occlusion sensitivity maps were used to derive information from classification decisions for NPM1 status prediction. DL models were implemented in Python version 3.7.9 with Keras version 2.3.0, TensorFlow version 2.1.2, and PyTorch version 1.5.0. Computations were performed using a high-performance computing system.

**Model performance and statistical analysis**

For performance analysis of the classification models, we used precision–recall curves and receiver operating characteristics (ROC) with the area under the curve (AUC). Precision is the fraction of true positives among all positive predictions of the DL model while recall is the fraction...
of all positive predictions of the DL model among all relevant events. The final models were evaluated on the validation set that was withheld from model training. To compare NPM1 VAF the Mann–Whitney U test was used.

Computational and statistical analysis was performed in Python (version 3.7.9) and R (version 4.0.3).

RESULTS

DL accurately distinguishes between BMS of AML patients and healthy bone marrow donor samples

We retrospectively identified 1251 AML patients, 386 of which harbored mutated NPM1 according to molecular analyses.

Detailed information on patient characteristics and controls is provided in Table 1. A total of 94,162 individual cells were manually segmented to iteratively train the FRCNN. Subsequently, automatic cell segmentation with the FRCNN achieved a mean average precision and a mean average recall of both 0.97 at an intersection over union ratio of 0.5. Inaccuracies were mostly due to overlapping cells. We then applied a CNN-based binary classification model on the previously segmented images to distinguish between cell types and characteristics and aggregated results were used by an ENN to distinguish between AML and healthy donor samples. We found this multistage approach to substantially increase accuracy over simple whole image
Further, we investigated whether DL could predict the mutational morphologic features and to balance the data. Weight decay of 0.0003 is utilized to prevent overfitting and the data was divided into training and test set with a split of 4:1. The model achieved an accuracy of 0.86 for NPM1 prediction and an AUROC of 0.92 (95% CI: 0.8768–0.9631; Fig. 3C). Table 2B shows the distribution of correctly and incorrectly identified NPM1-mutated and NPM1 wild-type samples in the validation set. Classification on single cells compared to whole image classification did not improve accuracy. To identify key morphological features that led the DL model to the prediction of the respective mutation status we used occlusion sensitivity maps (Fig. 4). This method iteratively blocks pixels of an image from being evaluated by the DL model for classification, which may reduce its predictive capabilities. Thereby, image areas that are essential for high accuracy can be detected as they greatly reduce model performance when being blocked (Fig. 4ii, iii). By analyzing the heatmaps, we observed that the prediction of mutated NPM1 was associated with a pattern of condensed chromatin and perinuclear lightening zones in myeloblasts (Fig. 4a, orange arrows indicate examples). The prediction of NPM1 wild-type was driven by prominent nucleoli (Fig. 4b, yellow arrows indicate examples) which could only very rarely be observed in samples with mutated NPM1 and in that context led to misclassification (false negatives). We further analyzed patient samples from the validation set grouped by NPM1 mutation status and true or false predictions given by the DL model regarding clinical and molecular data. NPM1-mutated AML samples that were correctly identified by the model (true positives) had a significantly higher median VAF than NPM1-mutated AML samples that were misclassified (false negatives) (true positives: 0.41 [95% CI: 0.39–0.42] vs. false negatives: 0.31 [95% CI: 0.1–0.42], p = 0.018, Fig. 5). Further, the rate of patients with therapy-associated AML (tAML) was significantly higher among false negatives compared to true positives (27.3% vs. true positives: 4.1%, p = 0.02) and false negatives had a significantly lower median white blood cell count (WBC) (false negatives 13.16 Gpt/l [IQR:22.25–28.57] vs. true positives: 37.48 Gpt/l [IQR:17.84–84.95], p = 0.007) and a trend for lower blast counts in peripheral blood (false negatives 25.5% [IQR: 4.75–38.5] vs. true positives: 52.5% [IQR: 16–75.25], p = 0.062). No significant differences for age, sex, ELN2017 risk category, absence or presence of a complex karyotype, bone marrow blast count, Hb, and platelet count were detected. For patients with wild-type NPM1 AML, there was a trend for lower median WBC for true negatives (3.54 Gpt/l [IQR: 1.52–19.82] vs. false positives 11.3 Gpt/l [IQR: 3.95–36.849], p = 0.095), but age, sex, ELN2017 risk category, AML type (de novo, secondary or therapy-associated), absence or presence of a complex karyotype, bone marrow or peripheral blast count, Hb and platelet count showed no differences. As another internal sanity check, we applied the pretrained classifier to the healthy bone marrow donor image data set and found that 214/236 (91%) of cases were correctly identified as NPM1 wild type while only 22/236 (9%) were labeled as NPM1 mutated (false positives). However, we want to point out that the NPM1 classifier has never been trained on healthy controls. Considering its AML-specific training, the very low false-positive rate on newly presented and differently structured image data of healthy controls underlines the distinct morphology picked up by the classifier for correct predictions in NPM1-mutated AML.

### Table 1. Patient characteristics.

| Parameter | All AML samples | NPM1-mutated AML | NPM1 wild-type AML | Bone marrow donors |
|-----------|-----------------|------------------|--------------------|--------------------|
| N         | 1251            | 386              | 865                | 236                |
| Age, median (IQR) | 57 (38–67)      | 57 (49–66)       | 54 (38–64)         | 31 (25–39)         |
| Sex, n (%) |                  |                  |                    |                    |
| Male      | 668 (53.4)      | 173 (44.8)       | 495 (57.2)         | 70                 |
| Female    | 583 (46.6)      | 213 (55.2)       | 370 (42.8)         | 30                 |
| AML type, n (%) |            |                  |                    |                    |
| De novo   | 969 (77.7)      | 339 (88.3)       | 630 (73)           | /                  |
| sAML      | 177 (14.2)      | 24 (6.2)         | 153 (17.7)         | /                  |
| tAML      | 101 (8.1)       | 21 (5.5)         | 80 (9.3)           | /                  |
| ELN2017 risk, n (%) |        |                  |                    |                    |
| Favorable | 380 (33)        | 277 (78)         | 111 (13.8)         | /                  |
| Intermediate | 521 (45.3)  | 75 (21.1)        | 446 (55.5)         | /                  |
| Adverse   | 249 (21.7)      | 3 (0.8)          | 246 (30.6)         | /                  |
| PB blasts, median (IQR) |        |                  |                    |                    |
| 23.5 (4–60) | 38 (11–72.5)  | 18 (2–51)        | /                  | /                  |
| BM blasts, median (IQR) |        |                  |                    |                    |
| 60.5 (40–80) | 73.5 (54–85)  | 54 (37–75)       | /                  | /                  |

Patient characteristics for the AML and control (bone marrow donors) cohort. The AML cohort is further subdivided by NPM1 mutation status. AML type was defined according to the WHO 2016 classification. sAML secondary AML, tAML therapy-associated AML, PB peripheral blood, BM bone marrow, N/n number, IQR interquartile range.
Interestingly, when we reviewed patient chart data and molecular results in the validation set, we found one sample that was incorrectly labeled as mutated NPM1, but was in fact wild-type NPM1, and the corresponding BMS image was correctly identified as such by the DL model.

**DISCUSSION**

We here present a machine learning approach for cell segmentation and image classification which provides a fast, scalable, and highly accurate method to identify AML samples from bone marrow cytomorphology. Our FRCNN achieved a cell segmentation accuracy of 0.97 from BMS. The binary classification model showed an AUC of 0.97 for both the ROC and the precision–recall curve and a micro-average accuracy of 0.91 distinguishing AML vs. healthy bone marrow donor samples. Our model can potentially be applied in initial diagnosis when a case of suspected AML is evaluated upon first contact in a hematologic center. It operates autonomously once BMS images are uploaded and detects AML with high accuracy. The model could operate synchronously with lab technicians to flag cases that are highly suspicious of AML for fast evaluation by experts while results from other diagnostic procedures like flow cytometry, cytogenetics, and molecular genetics are still pending. However, a human-in-the-loop approach is still needed as we manually selected representative regions of the BMS for evaluation by the DL model. It is to be noted that dysbalanced patient/control numbers were accounted for by image augmentation to balance the data sets for proper training of the classifiers.

The model was tested on a validation set of (A) 48 healthy controls and 251 AML patients. Misclassifications were 11% false positives (healthy controls misclassified as AML) and 13% false negatives (AML patients misclassified as healthy). For binary classification of NPM1 mutation status, the validation set was comprised of 77 patients with mutated (mNPM1) as well as 173 patients with wild-type (wtNPM1). Misclassifications were 14% false positives (wtNPM1 patients predicted to have mNPM1) as well as 14% false negatives (mNPM1 patients predicted to have wtNPM1). It is to be noted, that dysbalanced patient/control numbers were accounted for by image augmentation to balance the data sets for proper training of the classifiers.

### Table 2. Classification accuracy in the validation set.

| (A) AML vs. control | Prediction by deep learning | Healthy control | AML |
|---------------------|-----------------------------|-----------------|-----|
| Ground truth        | 43 (89%)                    | 5 (11%)         |     |
| Healthy control     | 28 (13%)                    | 223 (87%)       |     |

| (B) mNPM1 vs. wtNPM1| Prediction by deep learning | wtNPM1 | mNPM1 |
|---------------------|----------------------------|--------|-------|
| Ground truth        | 149 (86%)                  | 24 (14%)|       |
| wtNPM1              | 11 (14%)                   | 66 (86%)|       |

The model was tested on a validation set of (A) 48 healthy controls and 251 AML patients. Misclassifications were 11% false positives (healthy controls misclassified as AML) and 13% false negatives (AML patients misclassified as healthy). For binary classification of NPM1 mutation status, the validation set was comprised of 77 patients with mutated (mNPM1) as well as 173 patients with wild-type (wtNPM1). Misclassifications were 14% false positives (wtNPM1 patients predicted to have mNPM1) as well as 14% false negatives (mNPM1 patients predicted to have wtNPM1). It is to be noted, that dysbalanced patient/control numbers were accounted for by image augmentation to balance the data sets for proper training of the classifiers.
with cup-like blast morphology [36, 37]. When analyzing the features that the model used for NPM1 classification with occlusion sensitivity maps, we found so far unreported features like a pattern of condensed chromatin accompanied by perinuclear lightening zones for NPM1-mutated blasts. We observed prominent nucleoli in myeloblasts as a feature the DL model derived to predict wild-type NPM1 AML while these could only rarely be observed in NPM1-mutated AML samples and then led to misclassification by the model. Further, we found a significantly higher VAF in NPM1 true positives while the group of false negatives was comprised of a significantly higher rate of tAML. Wild-type NPM1 serves as a critical structural protein of the nucleolus, but mutations lead to a delocalization to the cytoplasm [38]. This process is partially triggered by insertions causing a frameshift of the C-terminal end of NPM1 and the formation of nuclear export signals [39, 40]. Weakened anchoring and predominant export signals subsequently result in increased nuclear export of NPM1 [38]. Arguably, a cytomorphologic correlate of this process may be the presence of prominent nucleoli in wild-type NPM1 AML and the absence thereof in mutated NPM1 AML—both detected as highly predictive features by our DL model.

Our study shows that DL can derive morphologic features from cytomorphology that predict mutation status. Future work will focus on other clinically important mutations and their morphologic imprint that DL may be able to pick up. In line with our findings, a recent study showed that DL can associate the morphology of myelodysplastic syndromes (MDS) with distinct genetic imprints [41]. However, in order to be integrated into clinical practice, machine-learning models need to be accurate and generalizable. As their development is complex, collaborations between physicians and software engineers is needed in an iterative approach to increase model performance. Since the majority of recently proposed machine-learning models—along with our model—are built on retrospective data, future studies will have to implement such models in a prospective setting to confirm their diagnostic value [42].

![Fig. 4](image-url) Application of occlusion sensitivity maps to detect features derived by deep learning for the prediction NPM1 mutation status in AML. Representatives images from bone marrow samples from a a patient with mutated NPM1 AML and b a patient with wild-type NPM1 AML. (i) Bone marrow aspirates were stained with the May–Grunwald–Giemsa method. Pictures were taken at 50-fold magnification using a Nikon ECLIPSE E600 microscope with a mounted Nikon DSFi2 camera. Images were processed using Nikon Imaging Software Elements D4. Scale bar = 10 µm. (ii) Heatmap of occlusion sensitivity maps generated in Python. The scale indicates the importance of certain image areas for correct class prediction: the more intensively green an area is the more important it is for correct class prediction. The heatmap shows a cell-specific class evaluation by the deep learning model. (iii) Masked image overlay of (i) and (ii) generated in Python showing areas the deep learning model focused on. Bright image areas are more important for class predictions. The orange arrows in (a, i) point to examples of cells with condensed chromatin and perinuclear lightening zones the deep learning model picked up for prediction of mutated NPM1. The yellow arrows in (b, i) point to examples of cells with prominent nucleoli the deep learning model picked up for prediction of wild-type NPM1.

![Fig. 5](image-url) Variant allele frequency of NPM1 true positives and NPM1 false negatives. Box-and-whisker plot for variant allele frequency (VAF) of mutated NPM1 AML samples that were correctly identified as such by the deep learning model (true positives) and those that were misclassified (false negatives) compared by the Mann–Whitney U test.

with the heterogeneity of cell morphology as well as close proximity of cells, disease...
classification from bone marrow is much more complex than in peripheral blood. Our use case to delineate AML from healthy bone marrow serves as groundwork for more complicated applications of CNNs in bone marrow morphology. AML is defined by bone marrow blast count [1] and CNNs can use a ratio of blasts to accurately detect AML. However, more complex use cases such as reactive bone marrow changes, benign disorders such as vitamin B12 deficiency, or hematologic neoplasms such as MDS are associated with subtle changes of cell morphology [43, 44]. In this scenario, CNNs have to be trained to accurately detect and assign such morphologic changes to the respective disorders. Mori et al. [45] recently used CNN-guided detection of decreased granules—one of the most common dysplastic changes in MDS—and report high accuracy for their classifier based on the ResNet-152. Accordingly, integrated analysis of more complex morphologies can potentially be achieved by feature engineering using a knowledge bank of expert-annotated cells with sufficiently sized training sets per morphologic feature (conceivably in the four- to five-digit number range). Since many hematologic neoplasms are rare disease entities, the development of such a large database requires extensive cooperation and data sharing between institutions and countries to ideally provide an open-source bone marrow database where independent ML models can be trained on analogous to existing cancer data bases such as The Cancer Genome Atlas [46]. Nevertheless, samples need to be properly anonymized to warrant patient data safety. If maintained and funded properly, such a database may vastly accelerate the development of clinically relevant computer vision tools for hematologic diagnostics. Standardization of data acquisition and accessible documentation of methodologies should be implemented to limit bias inherent to local methodologies of digitizing BMS and reporting patient data. Further, an integration of different diagnostic modalities such as cytomorphology both of bone marrow and peripheral blood, flow cytometry as well as genetic and clinical data seems warranted to build ML models that may aid in clinical decision making since evaluating only one modality at a time is insufficient for accurate diagnosis. Ensemble learning could be used to integrate the outputs of different ML models for different diagnostic modalities and provide a comprehensive and interpretable output to the clinician. Future work will focus on the extension of our ML pipeline for other use cases as well as different diagnostic modalities. As our study was limited to our center only, future studies will focus on transferability.

In conclusion, we here present a DL approach for the fast and accurate detection of AML from bone marrow cytomorphology. Our DL model accurately predicts NPM1 mutation status and derived so far unreported morphologic features that indicate absence or presence of NPM1 mutations from myeloblast morphology. This approach can be implemented to aid in clinical decision making, accelerate diagnosis, and may serve as a proof-of-concept for further studies of genetic imprints on disease morphology using DL.

**DATA AVAILABILITY**

De-identified original BMS image data that supported the findings of this study are publicly available under https://www.kaggle.com/sebastianriechert/bone-marrow-slides-for-leukemia-prediction.

**CODE AVAILABILITY**

Python code for the DL models developed and implemented for the purpose of this study is publicly available under https://github.com/TimSchmittmann/DL_detection_of_AML_from_BMS and https://github.com/SebastianRiechert/autofcrnn and https://github.com/SebastianRiechert/npm1-training.

**REFERENCES**

1. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.
2. Bain BJ, Béné MC. Morphological and immunophenotypic clues to the WHO categories of acute myeloid leukaemia. Acta Haematol. 2019;141:232–44.
3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Brit J Haematol. 1976;33:451–8.
4. de Thé H, Chomienne C, Lanotte M, Lorenzo VF, Nakase K, Kobayashi T, et al. Characteristics of t(8;21) acute myeloid leukaemia (AML) with additional chromosomal abnormalities: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML. Leukemia. 2003;17:713–7.
5. Falini B, Martelli MF, Bolli N, Sportoletti P, Liso A, Tiacci E, et al. Acute myeloid leukaemia with mutated nucleophosmin (NPM1): is it a distinct entity?. Blood. 2011;117:1109–20.
6. Grimwade D, Ivey A, Huntly BIP. Molecular landscape of acute myeloid leukaemia in younger adults and its clinical relevance. Blood. 2016;127:29–41.
7. Arber DA, Orazi A, Hasserkjær R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.
8. Rose D, Hafelerach T, Schnitger S, Perglerová K, Kern W, Hafelerach C. Specific patterns of molecular mutations determine the morphologic differentiation stages in acute myeloid leukemia (AML). Blood. 2016;124:2388–2388.
9. Dasarajru S, Huo M, McCalla S. Detection and classification of immature leukocytes for diagnosis of acute myeloid leukaemia using random Forest algorithm. Bioengineering (Basel). 2020;7:120.
10. Fuentes-Arderiu X, Dot-Bach D. Measurement uncertainty in manual differential leucocyte counting. Clin Chem Lab Med. 2009;47:112–5.
11. Križhevsky A, Sutskever I, Hinton GE. ImageNet classification with deep convolutional neural networks. Commun ACM. 2017;60:84–90.
12. Jain AK, Jianchang M, Mohiuddin KM. Artificial neural networks: a tutorial. Computer. 1996;29:31–44.
13. Basheer IA, Hajmeer M. Artificial neural networks: fundamentals, computing, design, and application. J Microbiol Methods. 2000;43:3–3.
14. Guo Y, Liu Y, Oerlemans A, Lao S, Wu S, Lew MS. Deep learning for visual understanding: a review. Neurocomputing. 2016;187:27–48.
15. Rodellar J, Alvarez S, Acevedo A, Molina A, Merino A. Image processing and machine learning in the morphological analysis of blood cells. Int J Lab Hematol. 2018;40(5):46–53.
16. Matek C, Schwarz S, Speikermann K, Marr C. Human-level recognition of blast cells in acute myeloid leukaemia with convolutional neural networks. Nat Mach Intell. 2019;1:538–44.
17. Ahmed N, Yigit A, Isik Z, Alpkocak A. Identification of leukemia subtypes from microscopic images using convolutional neural network. Diagnostics (Basel). 2019;9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787617/.
18. Röllig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornhäuser M, et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood. 2010;116:971–8.
19. Schach M, Parmentier S, Kramer M, Ilmer T, Stolzel F, Röllig C, et al. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol. 2013;31:2094–102.
20. Buchner T, Berdel WE, Hafelerach T, Schnitger S, Hafelerach T, Serve H, et al. Long-term results in patients with acute myeloid leukemia (AML): the influence of high-dose AraC, G-CSF priming, autologous transplantation, prolonged maintenance, age, history, cytogenetics, and mutation status. Data of the AMLCG 1999 Trial. Blood. 2009;114:485–485.
21. Röllig C, Kramer M, Gabrecht M, Hänel M, Herbstr R, Kaiser U, et al. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients. Ann Oncol. 2018;29:973–8, 01.
22. Braes J, Amler S, Kreuzer K-A, Speikermann K, Lindemann HW, Lengersfeld E, et al. Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study. Leukemia. 2018;32:2558–71.
23. Röllig C, Serve H, Hüttrmann A, Noppenr R, Müller-Tidow C, Krag U, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukemia (SORMAL): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16:1691–9.
